The International Vitreoretinal B-Cell Lymphoma Registry: a protocol paper.

Autor:	Smith JR; College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia justine.smith@flinders.edu.au.; Queensland Eye Institute, Brisbane, Queensland, Australia., Farrall AL; College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia., Davis JL; Bascom Palmer Eye Institute, University of Miami, Miami, Florida, USA., de Boer JH; Department of Ophthalmology, University Hospital Utrecht, Utrecht, The Netherlands., Hall AJ; Department of Ophthalmology, Alfred Health, Melbourne, Victoria, Australia., Mochizuki M; Department of Ophthalmology and Visual Science, Tokyo Medical and Dental University, Tokyo, Japan., Sen HN; National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA., Takase H; Department of Ophthalmology and Visual Science, Tokyo Medical and Dental University, Tokyo, Japan., Ten Dam-van Loon NH; Department of Ophthalmology, University Hospital Utrecht, Utrecht, The Netherlands., Touitou V; Department of Ophthalmology, Sorbonne University, Hospital Pitié Salpêtrière, Paris, France., Vasconcelos-Santos DV; Department of Ophthalmology, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil., Wilson DJ; Department of Ophthalmology, Casey Eye Institute, Oregon Health and Science University, Portland, Oregon, USA., Yeh S; Cancer Immunology Research Program, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA.; Department of Ophthalmology and Visual Sciences, Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, Nebraska, USA., Radford MHB; Queensland Eye Institute, Brisbane, Queensland, Australia.; Faculty of Medicine, George E Palade University of Medicine, Pharmacy, Science and Technology, Târgu Mureș, Romania.; Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia.; Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.
Jazyk:	angličtina
Zdroj:	BMJ open [BMJ Open] 2022 Jul 28; Vol. 12 (7), pp. e060701. Date of Electronic Publication: 2022 Jul 28.
DOI:	10.1136/bmjopen-2021-060701
Abstrakt:	Introduction: Vitreoretinal lymphoma is a rare ocular cancer with high morbidity and mortality despite treatment. Diagnosis by cytopathology is often delayed, and various molecular and image-based investigations have been developed. Diverse treatments are used, but there is a limited medical evidence to differentiate their effectiveness. We designed an international registry that would collect diagnostic, treatment and outcomes data, to establish new evidence for the management of this cancer. Methods and Analysis: The International Vitreoretinal B-Cell Lymphoma Registry will accrue data retrospectively for individuals aged 18 years or older, diagnosed with new or recurrent vitreoretinal B-cell lymphoma on or after 1 January 2020. A steering committee of subspecialised ophthalmologists identified 20 key clinical data items that describe patient demographics, tissue involvements, diagnostic testing, ocular and systemic treatments and treatment complications, and visual acuity and survival outcomes. Customised software was designed to permit collection of these data across a single baseline and multiple follow-up forms. The platform collects data without identifiers and at 3 month reporting intervals. Outcomes of the project will include: (1) descriptions of clinical presentations, and diagnostic and therapeutic preferences; (2) associations between clinical presentations, and diagnostics and treatments, and between diagnostics and treatments (assessed by ORs with 95% CIs); and (3) estimations of rates of vision loss, and progression-free and overall survival (assessed by Kaplan-Meier estimates). Ethics and Dissemination: The registry has received Australia-wide approval by a national human research ethics committee. Sites located outside Australia are required to seek local human research ethics review. Results generated through the registry will be disseminated primarily by peer-reviewed publications that are expected to inform clinical practice, as well as educational materials. Competing Interests: Competing interests: None declared. (© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu